Chemotherapy plus immunotherapy for advanced childhood nose cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests if adding an immunotherapy drug (toripalimab) to standard chemotherapy works better than chemotherapy alone for children and teens with advanced nasopharyngeal cancer (a type of nose cancer). The goal is to improve outcomes for newly diagnosed patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 18 years old.
- You have been newly diagnosed with a specific type of nasopharyngeal cancer (non-keratinizing).
- Your cancer is stage 2 or 3, but not certain subtypes like T3N0 or T3N1 with only retropharyngeal lymph node spread.
- You are in good enough health to have a performance status of 0 or 1 (fully active or slightly limited).
- Your blood counts and liver/kidney function are within normal limits as confirmed by tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding toripalimab (an immunotherapy) to two different platinum-based chemotherapy regimens as initial treatment for locally advanced nasopharyngeal carcinoma. The goal is to see if this combination is more effective than standard treatment.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
This trial tests whether a targeted radiation therapy, combined with the immunotherapy drug toripalimab before and after treatment, can reduce side effects while still effectively treating nasopharyngeal cancer. It is for patients with certain tumor sizes or stages who have not had prior neck radiation or immunotherapy.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.